The pathogenesis of the bone disease of multiple myeloma.
about
Vertebral augmentation in patients with multiple myeloma: a pooled analysis of published case seriesMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingComputational modeling of interactions between multiple myeloma and the bone microenvironmentRunx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsTranscriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myelomaPlasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKLConsequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease.Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow nichesHypophosphatemic osteomalacia: an unusual clinical presentation of multiple myeloma.Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing.Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases.Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunitiesCharacterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma.Effect of The Receptor Activator of Nuclear Factor кB and RANK Ligand on In Vitro Differentiation of Cord Blood CD133(+) Hematopoietic Stem Cells to Osteoclasts.Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.Role of the osteoblast lineage in the bone marrow hematopoietic niches.Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.Tumor-host cell interactions in the bone disease of myeloma.The bone marrow stroma in hematological neoplasms--a guilty bystander.Evidence-based risk assessment and recommendations for physical activity clearance: cancer.Smoldering multiple myeloma: present position and potential promises.The osteoblastic niche in the context of multiple myeloma.The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell.Wnt/β-catenin signaling in bone marrow niche.Bone marker gene expression in calvarial bones: different bone microenvironments.Vesiculovirus neutralization by natural IgM and complement.A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
P2860
Q26866197-1032C951-7C5B-4383-855C-CF5528E47976Q28082335-6B1671D9-9AA0-4020-8956-D9D156ABD850Q28477867-AB92979D-B14A-40E7-8776-58D404EF5141Q30435146-216EF95C-5183-4373-991E-30E2F3DECDD7Q33564854-359115FC-08B5-44B6-89DD-DEC64F649655Q33786905-A9EF74DC-759E-4934-A4D0-14461EB4446AQ33953955-1D85DFDE-D051-4A22-9794-BF4E325E4A11Q34038854-ED5D1EBF-946D-4242-8768-D382694DF7B5Q34169968-809A5707-FF01-47AB-BB59-4325B55AF985Q34256144-4C56583D-5F08-4E7F-88B8-49EA2CBA725CQ34267974-3F551DFF-7814-4C61-8431-924387881555Q34418934-EF1732CB-8AFE-4A97-A9D9-AF18890306FAQ34485147-A717BBAB-5050-4E4D-9187-AFFEC5BA8660Q34501627-CCF8339F-6B20-4E1E-886F-C805D44998B8Q34806153-084367A8-BED5-49B1-8346-36982FF5EF2FQ35183526-2E9AFABA-9354-40DE-80A4-A3A6041545A1Q35291672-F25EB371-2C64-4856-A988-EA62EB154F6CQ35789434-654E8685-8071-4492-9B64-924FA56125EAQ35899430-54760B52-604D-40DA-BA31-4BF6AB8FF5AFQ36073020-A01A26FE-A3C2-43BB-8C8C-58D3DFC07A9FQ36402724-F24F880A-E48E-4874-B9DB-EB61818B4A46Q36447553-61FD0641-856E-43D2-9BAA-D71960E23F3AQ36932713-1E61E125-2496-4308-A7E1-6A2CBF24248AQ37232005-F27A4E48-BF21-4A4F-84CF-9AEF6707B96DQ37357828-28C808F0-25CE-4E4B-9449-AE827D2C35B6Q37365560-6D830E31-A945-4351-8476-620D8BFB7AECQ37396070-412F9A9B-84F9-4D84-AF13-E00F29FC2F8FQ37405603-8FB30940-D3FF-4327-911B-F3F893B09BCEQ37452148-42601519-49CA-420A-8973-0D2B04FA90D0Q37668104-20B75F63-A622-43A6-B573-C7879DD008BCQ37771082-54C50ECF-1755-497D-8006-69A5DD1AB736Q37859253-C07B6194-68E4-436B-8532-F5B6DAC54097Q37908085-F54AB9DB-48C9-47C3-80A3-9A5B0D7FF03FQ38151230-9C9F502F-5C84-4256-B8EA-D61B080332FDQ38271428-3407A848-50C8-48B4-87B4-C2E0C841BB95Q38569328-F9A5C107-AB81-4C19-8CF3-A302270B0986Q38609596-EC7878D5-1E63-4E5C-859B-8B9495E46D79Q38775716-A51E8E81-03E2-404C-9159-B477B4C004B9Q39013686-D16E94D8-EB0C-4C4C-8E44-691AEA6A7E78Q39024879-1E7B5C65-CCE0-4A07-A83B-E5761DF4DB19
P2860
The pathogenesis of the bone disease of multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The pathogenesis of the bone disease of multiple myeloma.
@en
The pathogenesis of the bone disease of multiple myeloma.
@nl
type
label
The pathogenesis of the bone disease of multiple myeloma.
@en
The pathogenesis of the bone disease of multiple myeloma.
@nl
prefLabel
The pathogenesis of the bone disease of multiple myeloma.
@en
The pathogenesis of the bone disease of multiple myeloma.
@nl
P2860
P1433
P1476
The pathogenesis of the bone disease of multiple myeloma
@en
P2093
Gregory R Mundy
Junling Zhuang
P2860
P304
P356
10.1016/J.BONE.2008.01.027
P577
2008-02-21T00:00:00Z